NEW YORK – GeneCentric Therapeutics announced Wednesday the initial closing of an $8 million Series C funding round to support the launch and commercialization of its GenomicsNext circulating tumor DNA (ctDNA) liquid biopsy platform.

纽约——GeneCentric Therapeutics公司周三宣布，已完成800万美元的C轮融资的初步交割，以支持其GenomicsNext循环肿瘤DNA（ctDNA）液体活检平台的推出和商业化。

Hatteras Venture Partners led the funding round, with participation from existing investors IAG Capital Partners, Alexandria Venture Investments, and Laboratory Corporation of America. Durham, North Carolina-based GeneCentric expects the new funds to provide a cash runway through next year.

Hatteras Venture Partners 领投了这一轮融资，现有投资者 IAG Capital Partners、Alexandria Venture Investments 和 Laboratory Corporation of America 也参与其中。位于北卡罗来纳州达勒姆的 GeneCentric 预计新资金将提供明年所需的现金支持。

'With a single blood sample from a cancer patient, our GenomicsNext liquid biopsy platform can determine the gene expression of drug target genes, molecular subtypes, and predictive gene signatures, in addition to mutations and fusions,' Mike Milburn, president and CEO of GeneCentric, said in a statement.

“通过癌症患者的单个血液样本，我们的GenomicsNext液体活检平台不仅可以确定药物靶基因的基因表达、分子亚型和预测性基因特征，还可以检测突变和融合，”GeneCentric公司总裁兼首席执行官迈克·米尔伯恩在一份声明中表示。

'We believe our unique fragmentomics technology will become the best-in-class application for yielding greater insights and biomarker coverage from liquid biopsies to better aid diagnosis and treatment selection for patients.'.

“我们相信，我们独特的片段组学技术将成为同类应用中的佼佼者，能够从液体活检中获得更多洞察和生物标志物覆盖范围，从而更好地帮助患者的诊断和治疗选择。”

Last year, GeneCentric launched its

去年，GeneCentric 推出了其

ExpressCT Liquid Biopsy platform

ExpressCT 液体活检平台

, which adapts RNA-based gene expression signatures to cell-free DNA liquid biopsy assays.

，它将基于RNA的基因表达特征应用于无细胞DNA液体活检分析。